Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Calliditas Therapeutics AB - American Depositary Shares (CALT)
Company Research
Source: PR Newswire
STOCKHOLM, April 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024."We were pleased to share additional analyses from the 2-year Phase 3 NeflgArd trial of Nefecon in IgAN at this year's World Congress of Nephrology," said Richard Philipson, Chief Medical Officer of Calliditas. "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."Poster presentation details are below and will be available on the Presentations and Publications page on the Calliditas' corporate website following the meeting.Poster Presentatio
Show less
Read more
Impact Snapshot
Event Time:
CALT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CALT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CALT alerts
High impacting Calliditas Therapeutics AB - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
CALT
News
- Calliditas Therapeutics' 2023 Annual Report PublishedPR Newswire
- Calliditas Therapeutics' 2023 Annual Report Published [Yahoo! Finance]Yahoo! Finance
- Calliditas Therapeutics' 2023 Annual Report PublishedPR Newswire
- Calliditas Announces Positive NefIgArd Open Label Extension Results [Yahoo! Finance]Yahoo! Finance
- Calliditas Announces Positive NefIgArd Open Label Extension ResultsPR Newswire
CALT
Analyst Actions
- 2/22/24 - HC Wainwright
CALT
Sec Filings
- 4/25/24 - Form 6-K
- 4/24/24 - Form 20-F
- 3/6/24 - Form 6-K
- CALT's page on the SEC website